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Introduction
Infection remains an important cause of mortality and morbidity in patients with Systemic Lupus Erythematosus (SLE). Severe infection occurred in 11-45% of SLE patients depending on case definition, study population, observation period, etc (1-7).
Although several centres reported their incidence of infection, specific studies on severe infection from large multicenter SLE cohorts are lacking. Roughly 30% of deaths in SLE patients are related to infections and recent data from a multicenter French registry suggests that overall mortality for infectious diseases in SLE is higher than thought (8) .
Additionally, severe infections account for 11-23% of all hospitalization in SLE patients (3, 9, 10) , with hospitalization rates for serious infections 12 times higher than that in patients without SLE (11) , thus forming a significant part of the direct health-related costs associated with SLE (12) .
Several factors are associated with a predisposition to infection in SLE patients, including disease-related factors, immunosuppressant and corticosteroid use and intrinsic immune deregulations (13) (14) (15) . However, the relative contribution of each is not well known and comprehensive infection risk factor analysis is lacking. To determine the density of incidence of severe infection, delineate any associated factors and explore its clinical impact, we analyzed cumulative infection data from the RELESSER-T registry (Spanish Society of Rheumatology Lupus Registryretrospective phase), a very large, non-selected multicenter, well-characterized SLE patient cohort containing abundant data on comorbidities (16).
Methods
Patients from the RELESSER-T registry who met at least 4 ACR-97 SLE criteria were included. The variables, definitions, processes and methodological characteristics of the registry have been previously described in detail (17, 18) . In short, RELESSER-T is a multicenter, hospital-based registry, with retrospective cross-sectional collection of data from a large representative sample of adult non-selected patients with SLE attending Spanish rheumatology services from the public national health system. The patients were consecutively included until deadline of the study. Forty-five centers were involved and all of the participating research carried a specific training on the study procedures and on the use of SLE assessment tools (i.e., activity, severity and damage indexes). A total of 359 variables per patient were collected, with highly standardized definitions, encompassing sociodemographic data, cumulative clinical and laboratory characteristics as well as comorbidities and Charlson index, all of which were retrospectively recorded until the last available visit per RELESSER, including deceased. SLICC/ACR/Damage index (SDI), Severity Katz index (SKI) (19) and activity (SELENA-SLEDAI) (S-SLEDAI) at the last visit (when enrollment occurred) were calculated. Regarding treatments, the use of glucocorticoids (GC) and immunosuppresants (IS) was recorded in three ways: "use at last visit", "any use" and "use at the time of the infection". Only in the case of antimalarials was time of exposure (months) also recorded.
The first patient was enrolled in October 2011 and data collection was completed in August 2012.
Severe infection was defined as either the need for hospitalization with parenteral antibiotherapy for a potentially fatal infection or death caused by the infection. Isolation of the causative agent was not required in every case, with final classification as an infection being made using standard clinical criteria. Nevertheless, just in case of noisolation, a strict clinical diagnosis of infection, with a response to antibiotics, was also classified as an infectious event. Only infections recorded during the follow-up period were included. We considered death due to infection only when it had a decisive influence on the death, based on RELESSER investigator criteria.
Statistical analysis
Numerical variables are expressed as mean and standard deviation for those having a normal distribution, and as median and interquartile range for non-normal distributions (Kolmogorov test). The categorical variables are described by absolute frequency and percentage.
The rate (density) of incidence of infection during periods of patient monitoring was calculated, comparing incidence densities based on exposure (assessed retrospectively) to various factors including comorbidities etc., and calculating the relative risks for each.
Survival analysis (Kaplan-Meier) was conducted to assess when and how frequently the infections occurred as a function of the length of the follow-up period. Subsequent comparisons between survival curves were made using a log-rank test.
Comparisons of numerical variables were performed using a Student t test or a MannWhitney U test, according to normality adjustments, and categorical variables using a Chi square (or Fisher's exact test as necessary).
To assess the temporal evolution, annual rates were smoothed using moving averages (five-year periods) to depict time trends, thereby avoiding short-term variations.
Variables reaching statistical significance in the bivariate analysis and those considered clinically meaningful (e.g., alcohol abuse etc.) were entered into a multivariate model (Cox proportional hazards regression) using the forward LR entering method. Given that the dependent variable (severe infection) corresponded to a model of "repeated events", a variation of the Cox model (Andersen-Gill), which takes into account the given circumstances, was also carried out (20 The main clinical characteristic of the cohort has been extensively described elsewhere (15) . The ACR97 SLE criteria distribution is showed in table 1. The median S-SLEDAI score at time of last evaluation was 2.00 (IQR: 4), median SDI was 1 (IQR: 2) and median SKI score was 2 (IQR: 2). SLE-related treatments at the time of the RELESSER-T assessment (corresponding to the last visit before enrolment), at the time of the infection, and cumulative figures are shown in Table 2 . GC doses at the infection time were: <10 mg/day 53.1%, between 10-30 mg/day, 30.2% and >30mg/day, 16.7%. Table 3 ). The rate of incidence of mycobacterial infections was 1/1000 patient-years. Analysing the soft rates (mobilemeans every 5 years), a steady incidence rate was observed throughout the follow-up period. However, when mycobacterial infection rates were analysed, the incidence rate showed an annual decrement (p=0.02).
Concerning localization, the respiratory tract was the most frequently involved (35.5%), followed by the urinary tract (15.0%) ( Table 3) . A total of 208 (5.7%) patients died during follow-up, 24.5% by infection. The predominant localization for the fatal infection was the circulatory stream (bacteraemia, regardless of their source) (42.0%), followed by respiratory-related ones (34.0%).
Bivariate analysis
Several variables were associated with severe infection in the bivariate analysis, with density of incidence serving as a dependent variable (table 4) Furthermore, when quintiles of time on antimalarials (months) were analyzed, we observed an inverse relationship with the incidence of severe infection; namely, a proportional decrease in the incidence ratio with each quintile, from RR: 1 for Q1 (9.4 months on antimalarials) to RR: 0,66 (95% CI: 0,53-0,84) for Q5 (68.3 months).
Specifically, antimalarial users suffered viral infections less frequently than non-users (2.8% in users vs. 5.8% in non-users, p<0.001).
GC use at the time of the infectious event was associated with increased viral (14.6% vs. 11.1%) and fungal infections (3.8% vs. 0.8%), with a higher percentage of agent isolations (75.8% vs. 62.8% in non-GC users) (p<0.0001).
We also observed an association between GC at time of infection and mycobacterium as an etiologic agent: 3.7% in GC users vs. 0.2% in non-GC users (any dose), p <0.00001.
As shown in Table 4 , there were differences in cumulative IS use between patients with and without severe infection. Interestingly, 45.1% of patients that died by infection were on IS at that time vs. 9.6% of the surviving patients with severe infection (p<0.001).
Furthermore, 45.1% of the patients that died by infection were on GC (> 10 mg/day) vs. 
Multivariable analysis
In the Cox proportional-hazards regression model, which used time until first infection as the dependent variable, the following were associated with severe infection: age at diagnosis, Latin-American ethnicity, any history of glucocorticoid (≥10 mg/day), immunosuppressor or tobacco use, time on antimalarials (months), hospitalization due to SLE, renal involvement, SKI, and SDI (Table 5) (Table 5) , although immunosuppressant use, time on antimalarials and SDI lost statistical significance. Worth noting, however, is that previous severe infection reached significance only in the last model.
Discussion
The incidence of severe infection in SLE patients in the RELESSER registry (19.3%) was not very different than previous reports involving other large cohorts (4, 9, 21, 22), although certainly lower than in previous studies from monocentric cohorts in Spain, ranging from 29 to 38% (23, 24) , or than was recently reported by Feldman et al in a study involving an extensive administrative SLE database from the USA (25) .
Differences in patient selection and/or time of follow-up could explain these discrepancies or, as in the case of the North American cohort, the explanation might lie rather in ethnic or heath system differences. In fact, these patients were treated under Medicaid, a public health insurance program for low-income individuals, a socioeconomic status that could influence the infection risk (25) .
Consistent with most other studies, the RELESSER data confirm that respiratory infections are the most common severe infection in SLE (3, (21) (22) (23) (24) (25) (26) (27) (28) .
Regarding aetiology, bacteria were the most common agent involved followed by virus and fungus, which is also consistent with previous reports (25, 29) . The percentage of infections of unknown origin was relatively high (a third of the total), but that was not unexpected, given the high percentage of respiratory infections in this cohort. In fact, in SLE, as in the general population the aetiology of pneumonias remains unknown in ~50% of all cases (15, (30) (31) (32) .
There are scarce, reliable data concerning mycobacterium infections in the largest cohorts of SLE. The reported prevalence of M. tuberculosis infection in SLE patients ranges widely, from 5% to 30% (33, 34) . A total of 42 mycobacterium infections (3.5%) were registered in RELESSER, equivalent to a prevalence of 1.14% in the global RELESSER cohort. This prevalence is higher than the mycobacterium tuberculosis infection rate expected in the general Spanish population (34) . Furthermore, consistent with other studies (33, 35, 36 ), we found a higher proportion of extrapulmonary mycobacterium infections than expected, with an even higher percentage of extrapulmonary (vs. pulmonary) in our patients (57.1%). Additionally, we observed that this infection tended to appear during the first years of the SLE course and was associated with GC use at the time of infection, suggesting a relationship exists between higher disease activity and higher levels of immunosuppressive therapy.
We found an association, previously unreported, between tobacco use and recurrent severe infection in the RELESSER database. This is not surprising, since active smoking increases the risk of developing community-acquired pneumonia in the general population (37, 38) . Intriguingly, despite the fact that pneumonia is the most common severe infection in SLE, studies specifically addressing pneumonia in SLE have failed to demonstrate tobacco use as a specific risk factor (15, 31) . This apparent absence of association could be explained by its limited statistical power or, alternately, tobacco use could be a risk factor for any type of infection, not just respiratory ones. In fact, tobacco use increases an individual's susceptibility to bacterial infections in general, compromising the anti-bacterial function of leukocytes, including neutrophils, monocytes, T and B cells (39) . In any case, we have demonstrated an association between tobacco use and respiratory infections in the RELESSER data.
According to our findings, a previous infectious event appears to increase the risk of a new infection in SLE patients, a fact only sporadically explored (40) . While this risk factor could be a mere consequence of persistent predisposing factors that increase the susceptibility to recurrent infections, our data provides information about the global risk of infection, shedding light on unknown predisposing factors.
The association of severe infection with IS or GC use is well known (1-5,13 ). Any use of GC ≥ 10mg increases the risk of infection in our study, and 84% of the patients were been treated with GC at the infection time. These findings reinforce the role of GC as severe infection risk factor in SLE. Perhaps more interesting from our analysis is that the use of these treatments at the time of infection increases the risk of mortality from severe infection. On the other hand, a negative association between antimalarials exposure time and severe infection was observed in our study, reinforcing the possible role these drugs play in protecting against infection, a finding previously reported (25, 27, 41, 42) . Our results, however, do not agree with the other available multicenter study, which analyzed the exposure time to antimalarials in the GLADEL cohort. In that multi-nation inception cohort, no association was found between infection prevalence or death by infection and antimalarial exposure time. However, the followup period in this study was relatively short, with low numbers of infection and lesser mean durations of antimalarial drug exposure (48.5 months vs. 78.4 in RELESSER) (43) . An alternative, and somewhat provocative, explanation could lie in ethnic factors, given the Latin-American origins of the entire GLADEL cohort. While those differences may reflect the low severity of lupus in the European Caucasian population, one could also speculate that antimalarials might be less effective in Hispanics. This would also explain why we found a higher incidence of severe infection in this ethnic minority in our own study. Interestingly, in our analysis, the association of exposure duration with antimalarials was independent of severity, as measured by a validated quantitative severity index. This suggests the absence of a cofounding variable since it points to a less severe cases bias. The alkalinization of phagolysosomes and the inhibition of DNA replication has been posited as one mechanism explaining the protective ability of antimalarials, particularly against intracellular microorganisms such a salmonella, viral agents, etc. (44) (45) (46) (47) (48) . Consistent with this, protection against viral infections was observed in our analysis.
Finally, the protective effect of the antimalarials on infection risk could be reduced by the tobacco use, even though both factors showed an independent effect on infection risk in our statistical models.
We identified age at diagnosis as an independent factor associated with infection in this study, even when adjusted for co-morbidity as measured by the Charlson comorbidity index. This finding suggests that lupus exerts perhaps more impact over the immune system with increasing age than previously realized, an explanation that makes biological sense. In fact, in the general population the incidence of pneumonia increases with aging (49). results are particularly interesting, given that the difference was adjusted by severity and that the Latin American patients from the RELESSER cohort lived in Spain during the observation period and had complete access to the same public and universal health system as native Caucasian patients. This suggests that ethnicity, and not simply severity or socioeconomic factors, influences the incidence of infection.
The primary objective of our study was to explore the differences between SLE patients with or without previous severe infection. According to our data, SLE patients with serious infection suffer more severe disease. Not only are they more frequently hospitalized for SLE activity, but they also seem to have lower survival rates than patients without such infections. An independent relationship between SLE severity and pneumonia has been previously reported (15) . This is not an unexpected finding given the fact that SLE itself entails several immunologic disorders predisposing individuals to infection (1, 14) . However, weighing the impact of severity and immunosuppressive treatment on severe infection incidence remains problematic due to the presence of collinearity, as the most severely affected patients tends to receive more immunosuppressive therapy.
Some limitations of this study must be acknowledged. Several variables, such as measures of activity and damage, were not documented at the time of infection due to the multi-purpose nature of the RELESSER-T registry, which was never specifically designed to study infection in SLE. Although its retrospective design has an inherent bias, we believe that a bias towards unreported infections was unlikely given the definition of severe infection used in our study, which encompassed hospitalization.
This definition of severe infection could exclude some patients suffering from pneumonia or others severe infections not subject to hospitalization. However, given the characteristics of our Sanitary Health System, where the vast majority of patients with severe infections are managed inpatient, we believe our cohort sufficiently comprehensive and representative of severe infection in SLE.
Concerning SLE characteristics and covariates, the large number of patients and the special standardization effort carried out (17) minimize the impact of the retrospective design in missing data and quality.
The relative rates of mortality by infection in SLE patients are consistent in most cohorts, accounting for at least a quarter of all deaths (2, 3, (51) (52) (53) . Interestingly, blood stream infections were the first cause of fatal infection in our cohort, supplanting respiratory-related causes at the top of the list. These results reinforce previous findings that lupus patients with bacteraemia episodes have poor outcomes (54) (55) (56) . Strategies to reduce bacteraemia-related mortality -such as immediate instauration of antibiotic therapy if sepsis is suspected and others (e.g., the so-called "surviving sepsis campaign" strategy) should be implemented with particular care in SLE febrile patients, particularly patients on IS (57) . In fact, delayed or inadequate antibiotic therapy was the most significant independent factor for mortality in SLE-infected patients from one intensive care unit (58).
Conclusions
Our results need to be confirmed in prospective studies; specifically, with a more exhaustive inclusion of variables related to infection. Nonetheless, several remarkable conclusions can be drawn from our data:
1. Severe infection is associated with severity and damage in SLE patients. There are ethnic differences in the prevalence of infection in SLE, with rates appearing to be higher in Latin Americans.
2. Respiratory bacterial infections are the most commonly found severe infection in SLE, although bacteraemia are more often fatal. Indeed, there is an urgent need to implement improvements in both the early detection and aggressive management of this dangerous complication of SLE.
A previous infectious event increases the risk of a subsequent infection in SLE
patients. Tobacco use seems to be a risk factor for severe infection in SLE patients. In addition, antimalarials exert a time-dependent protective effect. 
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